FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159221106> ?p ?o ?g. }

• W3159221106 endingPage "92" @default.
• W3159221106 startingPage "85" @default.
• W3159221106 abstract "Background . Breast cancer is one of the most common malignancies and one of the leading causes of cancer deaths among women in the Russian Federation. The prognosis of the disease is largely determined by the biological subtype of the tumor. Her2-positive breast cancer is characterized by an aggressive course and unfavorable prognosis. The use of pertuzumab, a recombinant humanized monoclonal antibody to the human epidermal growth factor receptor 2, significantly improved immediate and long-term treatment outcomes. The aim of the study was to evaluate treatment outcomes in patients with Her2-positive molecular subtype of breast cancer receiving chemotherapy combined with a dual anti-Her2 blockade, and to assess the intensity and incidence of side effects. Material and methods . Between 2015 and 2018, 37 patients with Her2-positive breast cancer received chemotherapy combined with a dual anti-HER2 blockade (docetaxel 75 mg/m2 i/v on day 1 + trastuzumab 6 mg/kg (loading dose 8 mg/kg) i/v on day 1 + pertuzumab 420 mg (loading dose 840 mg) i/v on day 1 once every 3 weeks). The mean age of the patients was 45.6 ± 11.6 years. Results. Neoadjuvant pertuzumab in combination with trastuzumab and docetaxel resulted in pathological complete response in 12 % of patients and pathological partial response in 36 % of patients. Among patients who received the above neoadjuvant therapy regimen, disease progression was observed in 4 % of patients. The most common side effects were weakness and fatigue (5.4 % of cases) and grade I–II leukopenia (5.4 %). Conclusion. The study demonstrated the efficacy of antitumor therapy with pertuzumab in combination with trastuzumab and docetaxel as well as the absence of severe side effects associated with this treatment regimen in patients with Her2-positive breast cancer." @default.
• W3159221106 created "2021-05-10" @default.
• W3159221106 creator A5000739349 @default.
• W3159221106 creator A5002237224 @default.
• W3159221106 creator A5021369656 @default.
• W3159221106 creator A5027876164 @default.
• W3159221106 creator A5031375375 @default.
• W3159221106 creator A5032386698 @default.
• W3159221106 creator A5048011091 @default.
• W3159221106 creator A5049877954 @default.
• W3159221106 creator A5052728033 @default.
• W3159221106 creator A5054202840 @default.
• W3159221106 creator A5057054024 @default.
• W3159221106 creator A5062511423 @default.
• W3159221106 creator A5063171351 @default.
• W3159221106 creator A5069124633 @default.
• W3159221106 creator A5078042460 @default.
• W3159221106 creator A5079504119 @default.
• W3159221106 creator A5082431798 @default.
• W3159221106 creator A5089906719 @default.
• W3159221106 date "2021-05-02" @default.
• W3159221106 modified "2023-09-27" @default.
• W3159221106 title "EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER" @default.
• W3159221106 cites W1996778928 @default.
• W3159221106 cites W2095861620 @default.
• W3159221106 cites W2123591186 @default.
• W3159221106 cites W2137228442 @default.
• W3159221106 cites W2151733225 @default.
• W3159221106 cites W2154299562 @default.
• W3159221106 cites W2588881638 @default.
• W3159221106 cites W2742282063 @default.
• W3159221106 cites W2921367120 @default.
• W3159221106 cites W2962837000 @default.
• W3159221106 cites W3012380787 @default.
• W3159221106 cites W956929748 @default.
• W3159221106 doi "https://doi.org/10.21294/1814-4861-2021-20-2-85-92" @default.
• W3159221106 hasPublicationYear "2021" @default.
• W3159221106 type Work @default.
• W3159221106 sameAs 3159221106 @default.
• W3159221106 citedByCount "1" @default.
• W3159221106 countsByYear W31592211062022 @default.
• W3159221106 crossrefType "journal-article" @default.
• W3159221106 hasAuthorship W3159221106A5000739349 @default.
• W3159221106 hasAuthorship W3159221106A5002237224 @default.
• W3159221106 hasAuthorship W3159221106A5021369656 @default.
• W3159221106 hasAuthorship W3159221106A5027876164 @default.
• W3159221106 hasAuthorship W3159221106A5031375375 @default.
• W3159221106 hasAuthorship W3159221106A5032386698 @default.
• W3159221106 hasAuthorship W3159221106A5048011091 @default.
• W3159221106 hasAuthorship W3159221106A5049877954 @default.
• W3159221106 hasAuthorship W3159221106A5052728033 @default.
• W3159221106 hasAuthorship W3159221106A5054202840 @default.
• W3159221106 hasAuthorship W3159221106A5057054024 @default.
• W3159221106 hasAuthorship W3159221106A5062511423 @default.
• W3159221106 hasAuthorship W3159221106A5063171351 @default.
• W3159221106 hasAuthorship W3159221106A5069124633 @default.
• W3159221106 hasAuthorship W3159221106A5078042460 @default.
• W3159221106 hasAuthorship W3159221106A5079504119 @default.
• W3159221106 hasAuthorship W3159221106A5082431798 @default.
• W3159221106 hasAuthorship W3159221106A5089906719 @default.
• W3159221106 hasBestOaLocation W31592211061 @default.
• W3159221106 hasConcept C121608353 @default.
• W3159221106 hasConcept C126322002 @default.
• W3159221106 hasConcept C143998085 @default.
• W3159221106 hasConcept C2779786085 @default.
• W3159221106 hasConcept C2781164504 @default.
• W3159221106 hasConcept C530470458 @default.
• W3159221106 hasConcept C71924100 @default.
• W3159221106 hasConceptScore W3159221106C121608353 @default.
• W3159221106 hasConceptScore W3159221106C126322002 @default.
• W3159221106 hasConceptScore W3159221106C143998085 @default.
• W3159221106 hasConceptScore W3159221106C2779786085 @default.
• W3159221106 hasConceptScore W3159221106C2781164504 @default.
• W3159221106 hasConceptScore W3159221106C530470458 @default.
• W3159221106 hasConceptScore W3159221106C71924100 @default.
• W3159221106 hasIssue "2" @default.
• W3159221106 hasLocation W31592211061 @default.
• W3159221106 hasLocation W31592211062 @default.
• W3159221106 hasOpenAccess W3159221106 @default.
• W3159221106 hasPrimaryLocation W31592211061 @default.
• W3159221106 hasRelatedWork W2534174115 @default.
• W3159221106 hasRelatedWork W2560406314 @default.
• W3159221106 hasRelatedWork W2593886517 @default.
• W3159221106 hasRelatedWork W2751857407 @default.
• W3159221106 hasRelatedWork W2760874931 @default.
• W3159221106 hasRelatedWork W377899687 @default.
• W3159221106 hasRelatedWork W4206213581 @default.
• W3159221106 hasRelatedWork W4214767076 @default.
• W3159221106 hasRelatedWork W4242374293 @default.
• W3159221106 hasRelatedWork W4286512930 @default.
• W3159221106 hasVolume "20" @default.
• W3159221106 isParatext "false" @default.
• W3159221106 isRetracted "false" @default.
• W3159221106 magId "3159221106" @default.
• W3159221106 workType "article" @default.